37results about How to "Reduce ischemia-reperfusion injury" patented technology

Disclosed is a therapy for alleviating ischemia-reperfusion injury, which has few adverse side effects and can inhibit the invasion of neutrophils and the activation of platelets during ischemia reperfusion. The therapy comprises administering a mixed gas through inhalation to a patient who is intended to receive reperfusion, for a period between a time point that is immediately prior to the initiation of the ischemia-reperfusion and a time point that is shortly after the initiation of the reperfusion, wherein the mixed gas comprises 21 to 98% of oxygen, 0.1 to 4% of hydrogen and 40 to 80 ppm of nitrogen monoxide, with the remainder being an inert gas such as a nitrogen gas and a helium gas.

The invention relates to the technical field of medical instruments and discloses a first-aid instrument for crush injury. The first-aid instrument comprises a microcontroller, a hemostasis air belt, a blood flow detecting device, a pressure device and a decompressing device. The blood flow detecting device is connected with the microcontroller and used for detecting blood flowing information in crush-injured limbs, transmitting blood blocking signals to the microcontroller when blood is blocked and transmitting blood flowing signals to the microcontroller when the blood flows. The pressure device is connected with the hemostasis air belt and the microcontroller and used for inflating the hemostasis air belt under the control the microcontroller to block blood flowing. The decompressing device is connected with the hemostasis air belt and the microcontroller and used for deflating the hemostasis air belt under the control of the microcontroller to recover blood flowing. The microcontroller is used for controlling the pressure device to inflate the hemostasis air belt and controlling the decompressing device to deflate the hemostasis air belt in circulation mode. By using a medical means of ischemic postconditioning, ischemia reperfusion damage on the crush-injured limbs after stress is removed is relieved, and a purpose of protecting the injured limbs is achieved.

Disclosed herein are compounds of formula (I) or pharmaceutical acceptable salts thereof, wherein A, X<1>, X<2>, R<1>, R<2>, R<3>, m, n, and p are defined in the specification. Compositions including the compounds which can be useful for inhibiting Rho kinase (ROCK) and methods for using the compositions are also described.

The invention provides a liver perfusate, which is prepared by 5,500 to 6,500 mg / L of sodium chloride, 250 to 350 mg / L of potassium chloride, 150 to 250 mg / L of calcium chloride, 3,000 to 3,200 mg / L of sodium lactate, 4 to 6 mmol / L of 1, 6-diphosphofructose, 5 to 15 mg / L of dexamethasone, 2.5 to 3.5 mmol / L of reduced glutathione, and 4 to 6mg / L of verapamil. The product has a simple formula, convenient configuration, low cost and proper potassium concentration, can be safely used for the preservation of isolated organs, more importantly can be applied to the perfusion protection of vivo organs, and can effectively prevent the injury of hepatic ischemia reperfusion. The invention also provides two preparation methods for the liver perfusate.

The invention discloses two bromophenol compounds and a pharmaceutical application of their pharmaceutically-acceptable salts, specifically an application in the preparation of a myocardial ischemia-reperfusion injury protection drug. The two compounds and their pharmaceutically-acceptable salts can protect cardiomyocytes during rat heart acute ischemia so as to make rat heart functions complete.After routine intravenous administration, SOD activity after myocardial ischemia-reperfusion is raised, myocardial compliance is improved, serum LDH, serum CK, serum cTnT and MDA level after myocardial ischemia-reperfusion is remarkably reduced, myocardial injury is minimized, and FasmRNA after myocardial ischemia-reperfusion can be remarkably inhibited and reduced so as to inhibit cardiomyocyte apoptosis after myocardial ischemia-reperfusion. Therefore, the two bromophenol compounds and their pharmaceutically-acceptable salts have a clear myocardial ischemia-reperfusion injury protection function, thus providing a new method and means for the clinical treatment of myocardial ischemia-reperfusion injury and opening up a new direction for clinical medication.

An exterior-applied baicalin medicine in the form of liquid or ointment is prepared from baicalin powder through proportionally mixing it with the water for injection, regulating pH=5.5-8.0, laying aside for at least one day, and filter to obtain liquid, or proportionally mixing it with medical alcohol, stirring, adding vaseline and stirring to obtain ointment. It can regulate immunity, protect liver and gallbladder, and treat infection and tumor.

The invention belongs to medical biology technology, and relates to an organ preservation solution and its preparation. According to the preparation steps per 1000ml, it comprises: taking 1.57mg of tetrahydrobiopterin and 6.92mg of diazoxide and dissolving them in 1ml of dimethyl sulfoxide As a mother liquor; prepare 0.1mol / L CaCl210ml for later use; add 800ml double distilled water into a 1000ml container, add KCl 1.12g, MgCl22.64g, mannitol 10.93g, histidine 4.63g, glutathione 0.92g, Sodium glutamate 3.74g, stir until clear; add sodium lactate 6.90ml, stir until clear; add 0.1mol / L CaCl22.5ml, stir until clear; add stock solution and mother liquor, stir until clear. The pH was adjusted to 7.3-7.5, the osmotic pressure was adjusted to 320Osm / L, and the volume was adjusted to 1000ml with double distilled water. Store at 4°C for low temperature storage.

The invention discloses a medicament for treating cardiovascular and cerebrovascular diseases, which comprises ginseng stems and leaves saponin extracted from ginseng leaves and stems, and bilobalide extracted from ginkgo leaves.

The invention discloses a cryogenic preservation method and a recovery method without ice crystals in a supercooled state, and relates to the technical field of cryogenic medicine. The method for cryopreservation without ice crystals in a supercooled state includes: adding an oil substance to a cryoprotective solution in which cells or tissues are suspended, so that the oil substance completely covers the surface of the cryoprotectant solution to form a sample, and the sample is cryopreserved. The application can inhibit the freezing of cryoprotective solution at ‑20℃~0℃, and has obvious effects of inhibiting the formation of ice crystals and preventing the growth of ice crystals, so that the use of cytotoxic cryoprotective solutions such as DMSO can be avoided in tissue cell banks, etc. It is more conducive to the construction of a safe and non-toxic biological sample bank. This application can perform cryopreservation of tissue cells for a longer time (>2 days) at lower temperatures, reducing ischemia-reperfusion injury, and the survival rate of tissue cells after resuscitation is higher, and can maintain the original biological properties.

The invention relates to the technical field of medical instruments and discloses a first-aid instrument for crush injury. The first-aid instrument comprises a microcontroller, a hemostasis air belt, a blood flow detecting device, a pressure device and a decompressing device. The blood flow detecting device is connected with the microcontroller and used for detecting blood flowing information in crush-injured limbs, transmitting blood blocking signals to the microcontroller when blood is blocked and transmitting blood flowing signals to the microcontroller when the blood flows. The pressure device is connected with the hemostasis air belt and the microcontroller and used for inflating the hemostasis air belt under the control the microcontroller to block blood flowing. The decompressing device is connected with the hemostasis air belt and the microcontroller and used for deflating the hemostasis air belt under the control of the microcontroller to recover blood flowing. The microcontroller is used for controlling the pressure device to inflate the hemostasis air belt and controlling the decompressing device to deflate the hemostasis air belt in circulation mode. By using a medical means of ischemic postconditioning, ischemia reperfusion damage on the crush-injured limbs after stress is removed is relieved, and a purpose of protecting the injured limbs is achieved.

The invention discloses a hepatic portal blood flow blocking device, which relates to the field of clinical medicine, and comprises a catheter, a blocking bag and a positioning head. The base end of the catheter is provided with a protective plug to prevent external impurities from entering the catheter; At least one layer of flexible layer material, the inner surface of the flexible layer or in the flexible layer is provided with linear support frames arranged at intervals, and the support frames are made of shape memory alloy; the flexible layer surrounds the interior to form a cavity; the end of the cavity The positioning head is formed by a protrusion away from the catheter. The center of the positioning head is provided with a pinhole-shaped through hole connecting the outside to the cavity. The positioning head is also covered with an annular positioning ring. It realizes the ability to reduce the requirements for ultrasound-guided technology and puncture technology during use, and realizes simple and rapid blood flow occlusion in the hepatic portal vein, so as to implement precise resection. The technical effect of reducing the chance of portal vein metastasis and improving the survival rate of patients in the perioperative period after surgery.

The present invention provides a controllable external input balloon for reducing ischemia-reperfusion injury, which relates to the field of interventional medical devices. It consists of mass pushing tube, proximal flexible tube, balloon, distal flexible tube, guide wire and flow control components. The flow control component consists of an external perfusion joint and a flow controller connected to the external perfusion joint through a catheter; controllable perfusion flow; after the balloon is inflated, the balloon is not released, and the controllable reperfusion balloon is injected in vitro through the external perfusion joint at the distal end of the balloon and the flow controller connected to the external perfusion joint through a catheter To control, the prepared perfusion solution can be used to slowly perfuse the infarct area or the distal end of the ischemic area to avoid ischemia-reperfusion injury; while perfusing the distal end, the balloon only needs to be expanded and released once, which can reduce or avoid vascular injury, Plaque shedding and no-reflow in distal vessels occurred.

The invention discloses an ice-crystal-free low-temperature preservation method in a supercooled state and an ice-crystal-free low-temperature recovery method in the supercooled state, and relates to the technical field of low-temperature medicine. The ice-crystal-free low-temperature preservation method in the supercooled state comprises the following steps: adding an oil substance into a cryoprotectant in which cells or tissues are suspended, allowing the oil substance to completely cover the surface of the cryoprotectant to form a sample, and carrying out low-temperature preservation on the sample. According to the invention, the cryoprotectant can be inhibited from freezing at a temperature of -20 DEG C to 0 DEG C, and the obvious effects of inhibiting ice crystal formation and preventing ice crystal growth are obtained, so a tissue cell bank and the like can be prevented from using cryoprotectants with cytotoxicity, such as DMSO (dimethylsulfoxide), and a safe and non-toxic biological sample bank is more favorably constructed. Compared with the prior art, the methods of the invention have the advantages that tissue cell cryopreservation can be performed for a longer time (longer than 2 days) at a lower temperature, ischemia-reperfusion injury is relieved, the survival rate of tissue cells after resuscitation is higher, and original biological characteristics can be kept.